tirzepatide from eli lilly Lilly's scores again, this time in 2 sleep apnea trials Eli Lilly (LLY) Gets Nod

Ozempic is considered a first-line treatment for Type 2 diabetes only if you have cardiovascular disease (CV disease) or are at high risk for CV disease

Furthermore, this triple-agonist mechanism distinguishes it clearly from earlier single and dual-agonist compounds

A 2019 study in experimental colitis models demonstrated that GLP-1 receptor activation reduced inflammatory markers and improved intestinal barrier function

Many supplements combine them for you

The results showed that after 52 weeks, almost half the participants taking Contrave saw at least a 5% reduction in weight

Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program